Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Asahi Kasei Pharma Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3294
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company’s portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescription drugs are used for the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome and lupus nephritis, and difficulty in urination. Asahi Kasei Pharma offers assay kits that determine glycemic control and detect prediabetes. The company’s pipeline includes candidates for acute exacerbation of idiopathic pulmonary fibrosis; chemotherapy-induced peripheral neuropathy; osteoporosis with high risk of fracture; Lupus nephritis and nephrotic syndrome; and for severe sepsis with coagulopathy. It manufactures pharmaceuticals and diagnostic kits at its manufacturing plants in Shizuoka, and Nagoya in Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.

Asahi Kasei Pharma Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 10
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 11
Evotec Enters into Agreement with Asahi Kasei Pharma 12
Orion Enters into Agreement with Asahi Kasei Pharma 13
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 14
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 15
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 16
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 17
Licensing Agreements 18
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 18
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 19
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 20
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 21
Asahi Kasei Pharma Corp – Key Competitors 22
Asahi Kasei Pharma Corp – Key Employees 23
Asahi Kasei Pharma Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Key Facts 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
XERIS Pharma Enters into Agreement with Asahi Kasei Pharma 10
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 11
Evotec Enters into Agreement with Asahi Kasei Pharma 12
Orion Enters into Agreement with Asahi Kasei Pharma 13
PeptiDream Enters into Research Agreement with Asahi Kasei Pharma 14
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 15
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 16
Hisamitsu Pharma Enters Into Co-Marketing Agreement With Asahi Kasei Pharma For HOB-294 17
Asahi Kasei Pharma Enters into Licensing Agreement with Sanofi 18
Asahi Kasei Pharma Enters into Licensing Agreement with Array BioPharma 19
Basilea Pharma Enters into Licensing Agreement with Asahi Kasei Pharma 20
Asahi Kasei Pharma Enters into License Agreement with Dong-A ST 21
Asahi Kasei Pharma Corp, Key Competitors 22
Asahi Kasei Pharma Corp, Key Employees 23
Asahi Kasei Pharma Corp, Other Locations 24
Asahi Kasei Pharma Corp, Subsidiaries 24

List of Figures
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Asahi Kasei Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sentara Healthcare Inc:企業の戦略的SWOT分析
    Sentara Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • AXO Science SAS:企業の製品パイプライン分析2018
    Summary AXO Science SAS (AXO) is a developer of high output and multi-parametric analysis solutions for characterizing biological samples. The company offers solutions such as blood genotyping, allergy diagnosis, cancer diagnosis, pathogens detection, customized assays, sperm tracker, microarray spo …
  • Dyo Boya Fabrikalari Sanayi ve Tic. A.S. (DYOBY):企業の財務・戦略的SWOT分析
    Dyo Boya Fabrikalari Sanayi ve Tic. A.S. (DYOBY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • EP Petroecuador:企業の戦略的SWOT分析
    EP Petroecuador - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Nuvaira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nuvaira Inc (Nuvaira), formerly Holaira Inc is an independent medical device company that strives to develop minimally invasive products for the treatment of obstructive lung diseases. It provides Lung Denervation System, a catheter-based system intended for asthma and chronic obstructive pu …
  • Enmax Corporation:企業の戦略的SWOT分析
    Enmax Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Elia System Operator SA (ELI):電力:M&Aディール及び事業提携情報
    Summary Elia System Operator SA (Elia) is a transmission system operator. It owns and operates high-voltage electricity transmission systems in Belgium and Germany. The company transmits electricity from generators to distribution system operators and industrial consumers. Elia also imports and expo …
  • Eiger BioPharmaceuticals Inc (EIGR):企業の財務・戦略的SWOT分析
    Summary Eiger BioPharmaceuticals Inc (Eiger), formerly Celladon Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercializationof novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which are …
  • Development Bank of Japan Inc:企業のM&A・事業提携・投資動向
    Development Bank of Japan Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Development Bank of Japan Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Helix Energy Solutions Group Inc (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Energy Solutions Group Inc (Helix Energy) is an oil and gas company that provides offshore energy services. The company provides well intervention, subsea engineering and contracting services. Its well intervention services comprise riserless intervention and riser based operations, st …
  • DBK Pharmaceutical:製薬・医療:M&Aディール及び事業提携情報
    Summary DBK Pharmaceutical (DBK Pharma) is a pharmaceutical company that develops, manufactures and markets pharmaceutical, herbal brands, food supplements, cosmetics and veterinary products. The company’s pharmaceutical products include chitocal capsule, debeskon, rentensar tablets, pressothioval, …
  • Marfrig Global Foods SA:企業の戦略・SWOT・財務情報
    Marfrig Global Foods SA - Strategy, SWOT and Corporate Finance Report Summary Marfrig Global Foods SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sidney Kimmel Comprehensive Cancer Center-製薬・医療分野:企業M&A・提携分析
    Summary Sidney Kimmel Comprehensive Cancer Center (Sidney Kimmel) is a healthcare service provider that concentrates on diagnosis, treatment, and prevention of cancer. The center’s specialties include cancer diagnostic and treatment planning, blood and bone marrow cancers, cancer immunotherapy, brai …
  • Kate Spade & Company LLC:企業の戦略・SWOT・財務分析
    Kate Spade & Company LLC - Strategy, SWOT and Corporate Finance Report Summary Kate Spade & Company LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • BioVentrix Inc-医療機器分野:企業M&A・提携分析
    Summary BioVentrix Inc (BioVentrix) is a medical device company that develops congestive heart failure treatment solutions. The company provides revivent myocardial anchoring systems that restore the size, volume and resulting function of the left ventricle for improving cardiac function in heart fa …
  • British American Tobacco Bangladesh:企業の戦略・SWOT・財務情報
    British American Tobacco Bangladesh - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco Bangladesh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Protalix BioTherapeutics Inc (PLX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients wi …
  • China Petrochemical Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary China Petrochemical Corp (Sinopec Corp) is a petroleum and petrochemical company. The company is engaged in the engaged in the exploration and production, pipeline transportation, and sale of petroleum and natural gas. It is also involved in the production, sale, storage and transportation o …
  • European Investment Bank:企業の戦略的SWOT分析
    European Investment Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Universal Power Group Inc (UPGI):企業の財務・戦略的SWOT分析
    Summary Universal Power Group Inc (UPG) a subsidiary of UPGI Holdings Inc, is a provider of electric mobility products. The company through its subsidiaries supplies and distributes batteries and related power accessories. It offers sealed lead-acid batteries, ap series batteries, hc series batterie …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆